ERBB2 and breast cancer: Biopsies retrieved 3 weeks after exposure to the HER2 targeting ADC TDM-1 in the adjuvant dynamic marker-adjusted personalized therapy optimising risk assessment and therapy response prediction in early breast cancer (WSG-ADAPT) trial demonstrated an increase in the number and density of tumour infiltrating T cells [147, 148].